CVRx (CVRX) recently announced the publication of new data supporting its Barostim technology for treating heart failure. The data was published in the Journal of the American College of Cardiology: Heart Failure. The publication builds on the data from the BeAT-HF trial published in 2024 in the European Journal of Heart Failure, demonstrating the long-term sustained symptomatic benefits of Barostim in heart failure patients with reduced ejection fraction. Shares of CVRX gained 3.2% on Friday on the announc ...